argenx SE announced that VYVGART demonstrated statistically significant efficacy in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis (oMG), achieving its primary endpoint with a p-value of 0.012. The study results showed meaningful improvements in ocular symptoms, including reduction in diplopia and ptosis, compared to placebo-treated patients. These findings represent a significant clinical milestone, as VYVGART would be the first targeted therapeutic specifically evaluated in this patient population if approved.
Ocular myasthenia gravis, characterized by weakness affecting the eye muscles, represents a subset of the broader myasthenia gravis disease spectrum. The positive trial results provide clinical evidence supporting the therapeutic potential of VYVGART, an neonatal Fc receptor (FcRn) antagonist previously approved for generalized myasthenia gravis, in this more localized disease manifestation.
Argenx intends to submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration seeking label expansion for VYVGART in oMG. The regulatory submission would mark the company's effort to broaden the drug's therapeutic indication within the myasthenia gravis disease category based on robust Phase 3 clinical trial data.